Eighty percent of patients with a subset of lymphoma saw their cancers shrink after taking zanubrutinib in a clinical trial.

The findings could lead to repurposing drugs for patients with the sometimes-fatal condition.

Researchers developed an HDL-mimicking nanoparticle that modified heart disease-related plaques in preclinical research.

70% of spending on “partial orphan” drugs – those approved to treat both rare and common diseases – goes toward treatment of common diseases.

Researchers continue to hone in on how best to prevent blood clots, which cause strokes and heart attacks, without unintended side effects.

Preclinical study identifies possible therapeutic target for cardiovascular risk factors that avoid the common problem of an increased risk of fatty liver disease.